Placebo Nitazoxanide

DRUG2 trials

Sponsors

Rutgers, The State University of New Jersey, University of Calgary

Conditions

ADHDADHD - Attention Deficit Disorder With HyperactivityADHD - Combined TypeCovid19SARS-CoV Infection

Phase 2

A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

TerminatedNCT04605588

Rutgers, The State University of New JerseySARS-CoV Infection, Covid19

Start: 2020-12-02End: 2021-02-04Updated: 2022-05-05

A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD

Not yet recruitingNCT07756255

University of CalgaryADHD, ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type

Start: 2026-08-31End: 2029-08-31Target: 64Updated: 2026-09-10

Related Papers

Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

Trials2022-07-227 citations